Aluminium and Alzheimer's disease

Area of Science:

• Neuroscience
• Toxicology
• Biochemistry

Background:

• The hypothesis linking aluminium (Al) to Alzheimer's disease (AD) neuropathology, including beta-amyloid plaques and neurofibrillary tangles (NFT), stems from early studies showing Al compounds induce NFT formation in animals.
• Research has indicated that Al affects cognitive functions in animals and humans with renal failure, and Al has been detected in brain tissues of AD patients.

Purpose of the Study:

• To critically evaluate the hypothesis that aluminium (Al) is a causative agent or risk factor in Alzheimer's disease (AD) development.
• To investigate the impact of Al exposure on cognitive function, particularly in vulnerable populations.

Main Methods:

• Review of extensive studies on AD pathology and Al-induced encephalopathy.
• Analysis of findings from electron probe and laser microprobe mass analysis (LAMMA) studies detecting Al in AD brain tissues.
• Consideration of research on Al's effects on cognitive function in experimental animals and humans.

Main Results:

• Extensive research indicates that Al does not cause the characteristic neuropathology of Alzheimer's disease.
• However, Al can impair cognitive functions under specific conditions, such as when the blood-brain barrier is compromised or in individuals with renal failure.

Conclusions:

• Aluminium is not a direct cause of Alzheimer's disease neuropathology.
• Al intake should be carefully controlled in individuals with renal failure, undergoing dialysis, or those with a damaged blood-brain barrier to prevent cognitive impairment.